HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life

Exclusion Criteria

• •They do not have one of the specified cancer types
• •Disease is recurrence / progression (either locally advanced or metastatic) at an existing cancer site
• •They are having treatment for a potentially curative recurrence of disease e.g. locally advanced disease (i.e. they have been previously treated for the same cancer)
• •They have metastatic disease from a cancer at another site (Previous diagnosis of cancer at any other site would not be grounds for exclusion unless disease was metastatic)
• •They have synchronous primary cancers involving two or more of the HORIZONS specified cancer types (Please exclude synchronous gynaecological primary cancers, synchronous breast and gynaecological primary cancers, synchronous breast and non-Hodgkin's lymphoma primary cancers and synchronous non-Hodgkin's lymphoma and gynaecological cancers)
• •COHORT-SPECIFIC ELIGIBILITY CRITERIA:
• •BREAST CANCER COHORT
• •Inclusion:
• •Women aged under 50 years old
• •Stage 1, 2 or 3 breast cancer
• •Have no distant metastases
• •Patients due to undergo neoadjuvant treatment should be approached before this starts
• •For those whose core biopsy shows ductal carcinoma in situ (DCIS) only but post-excision biopsy pathology confirms invasive cancer, approach should be made as soon as possible following diagnosis and completion of the baseline questionnaire should be prior to the start of adjuvant treatment
• •Exclusion:
• •Confirmed diagnosis of CIS (ductal or lobular) only
• •Men
• •NON-HODGKIN LYMPHOMA COHORT
• •Inclusion:
• •Any pathological diagnosis of Diffuse Large B Cell lymphoma (DLBCL) including;
• •Secondary transforming or transformed DLBCL which has transformed from an indolent/low grade lymphoma (most commonly Follicular Lymphoma) as long as the low grade lymphoma was not treated and this is a recent transformation for which curative intent treatment has not yet started.
• •Rare sub-types such as T cell rich Large B Cell Lymphoma and primary mediastinal (thymic) large B-cell lymphoma
• •Patients who have started steroid pre-phase treatment are eligible for approach before the start of chemotherapy.
• •GYNAECOLOGICAL CANCERS COHORT
• •ALL GYNAECOLOGICAL CANCERS
• •Synchronous gynaecological primary cancers. For example, synchronous ovarian and endometrial primary cancers.
• •OVARIAN CANCER SUB-COHORT
• •Borderline ovarian cancer
• •Germ cell tumour
• •Sarcoma
• •ENDOMETRIAL CANCER SUB-COHORT
• •Choriocarcinoma
• •Germ cell tumour
• •Sarcoma
• •CERVICAL CANCER SUB-COHORT
• •FIGO stage IA1
• •Cervical carcinoma in situ (CIS)
• •Sarcoma
• •Small cell cancer of the cervix
• •VULVAL CANCER SUB-COHORT
• •Basal cell carcinoma
• •Melanoma
• •Sarcoma
• •Vulval intra-epithelial neoplasia (VIN)